APCCC 2024 | Who can postpone salvage radiotherapy in biochemically recurrent prostate cancer?

Barbara Jereczek-Fossa, MD, PhD, University of Milan, Milan, Italy, discusses selecting patients with biochemically recurrent prostate cancer for postponing salvage radiotherapy. Emphasis is placed on prognostic factors such as prostate-specific antigen (PSA) doubling time and International Society of Urological Pathology (ISUP) grade. Studies from East Anglia University highlight improved survival rates with salvage radiotherapy in high-risk patients, though the benefit is less clear for low-risk patients. The discussion covers the risks associated with delaying therapy and anticipates the future use of tools like artificial intelligence and genomic testing to better guide treatment decisions. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.